Media Doctor Canada








"New treatment approved for kidney cancer"


Source: CBC.CA

Published: 01 Aug 2022

Category: Pharmaceutical

Rating: (1½ stars)

what they said (Hover the mouse cursor over underlined words for more info)

Health Canada has approved a new drug for advanced kidney cancer, the first new treatment option for the disease in more than a decade.
Renal cell carcinoma is the most common form of kidney cancer. In 2006, it will affect an estimated 5,000 Canadians, and 1,550 will die from the disease, according to the Canadian Cancer Society....

The original article can found in the Media Doctor archives.

how did it rate? (more information)

Criteria Rating
Total Score 3 of 11
Availability of Treatment Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Not Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Not Satisfactory (?)
Quantification of Benefits of Treatment Not Satisfactory (?)
Harms of Treatment Not Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Satisfactory (?)
Quantification of Harms of Treatment Not Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

This story is hampered by being particularly short, but even in the small amount of space used, it could have done a better job of providing meaningful information about this new treatment for kidney cancer. Among the story's chief flaws is an over reliance on the press release and the lack of any outside, or corroborating information. It may well be good news that a new cancer treatment is available for kidney cancer patients but anyone interested in gaining useful insights about this product will have to look elsewhere for information.

Even just a bit of simple digging would have made a much better and more informative experience for the reader. A quick search using google scholar ( turns up a Medscape article that provided a bit more information, such as the drug's approval coming from a multicenter, double-blind, phase 3 randomized trial in 769 patients, and that the drug improved "median progression-free survival (PFS)" relative to placebo was 167 vs 84 days.

Among the commonly reported adverse events are "diarrhea, rash/desquamation, fatigue, hand-foot skin reaction, alopecia, nausea, pruritus, hypertension, vomiting, and anorexia. Grade 3 and 4 adverse events were reported in 31% and 7% of patients receiving sorafenib compared with 22% and 6%, respectively, of those administered placebo".

public forum

(28 Nov 2021) kanadajohn writes,

"Nice! Well done! Many thanks. I found lots of intresting things here. All the best!
lortab lortab
auf baldiges Wiedersehen!"

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada